Compression the efficacy of Topiramate and Propranolol in patients with migraine

Compression the efficacy of Topiramate and Propranolol in patients with migraine with Aura

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201031049208N1

Enrollment

Registered

2020-11-08

Start date

2020-09-22

Completion date

Unknown

Last updated

2020-11-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine

Interventions

Intervention 1: Intervention group (1): Topiramate will be started at a daily dose of 25 mg and increased to 100 mg daily, depending on patient tolerance. The duration of taking the drug is three mont

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Age group 18 to 65 years History of migraine with Aura (according to the definition of the international classification of headache disorders) Patients with the frequency of migraine attacks at least once a week

Exclusion criteria

Exclusion criteria: Systolic blood pressure below 90 mmHg Heart rate below 65 beats per minute Incidence of tension-type headache attacks in the last month Previous history of analgesia or migraine specific medication History of known allergy to Topiramate or Propranolol History of kidney stone History of depression

Design outcomes

Primary

Measure	Time frame
Assessing the degree of disability. Timepoint: Before and after 3 months of taking the drug. Method of measurement: Migraine Disability Assessment (MIDAS) scale questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSaba Farashi

Ahvaz University of Medical Sciences

Farashi86.sf@gmail.com009861329235893

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026